Pharmacologic blockade of JAK1/JAK2 reduces GvHD and preserves the graft-versus-leukemia effect.
about
Risk of Infectious Complications in Hemato-Oncological Patients Treated with Kinase InhibitorsImmunological basis for treatment of graft versus host disease after liver transplant.Steroids Versus Steroids Plus Additional Agent in Frontline Treatment of Acute Graft-versus-Host Disease: A Systematic Review and Meta-Analysis of Randomized Trials.Biology of chronic graft-vs-host disease: Immune mechanisms and progress in biomarker discovery.CML cells actively evade host immune surveillance through cytokine-mediated downregulation of MHC-II expression.Emerging drugs for graft-versus-host disease.Mechanistic approaches for the prevention and treatment of chronic GVHD.Novel targets in the treatment of chronic graft-versus-host disease.Compassionate use of ruxolitinib in acute and chronic graft versus host disease refractory both to corticosteroids and extracorporeal photopheresis.Targeting JAK2 reduces GVHD and xenograft rejection through regulation of T cell differentiation.Ruxolitinib as a promising treatment for corticosteroid-refractory graft-versus-host disease.New and emerging therapies for acute and chronic graft versus host disease.The Role of Janus Kinase Signaling in Graft-Versus-Host Disease and Graft Versus Leukemia.Application of proteomics to graft-versus-host disease: from biomarker discovery to potential clinical applications.Ruxolitinib: a steroid sparing agent in chronic graft-versus-host disease.Ruxolitinib for the treatment of patients with steroid-refractory GVHD: an introduction to the REACH trials.Targeting Aurora kinase A and JAK2 prevents GVHD while maintaining Treg and antitumor CTL function.Recipient and donor JAK2 46/1 haplotypes are associated with acute graft-versus-host disease following allogeneic hematopoietic stem cell transplantation.T-Cell Manipulation Strategies to Prevent Graft-Versus-Host Disease in Haploidentical Stem Cell Transplantation.
P2860
Q26851417-94F0E4C6-0489-4C8D-8F3F-CFA11FC347D4Q37114440-F71AD03E-4C9C-4149-BFD1-C7C32F74CEE6Q37302887-9BD86460-7C32-4728-ADB6-62E65DB4F6A3Q37522548-053DE8B1-F04C-44D7-AB15-8084FBB3ECB0Q37638846-D6CC7DCE-0B41-4F95-869C-E1F52413C6A5Q38786084-FFB3A618-3AD1-4062-BA6E-1BE2D690427BQ39002166-2C44C51D-BD45-4703-A159-46B15C687A44Q39023963-789ED917-3D0D-4D0F-B10A-6697EA40D273Q47114304-55E698C1-E1C9-4CAC-8211-579496C1E4B4Q48139357-EDD4E9B7-06B4-4263-8175-E434323B201BQ48231285-548CC668-6DC5-4EB7-B3D5-765DE6A9A7D2Q49238507-5A520F1E-3005-4FBD-94C7-56812B55A11CQ49384876-5C2A52F7-1F3C-4263-A860-2D4F82579B68Q49645938-F1DCE6A7-28BF-4C12-871C-DD81E62854C1Q49724160-13D10738-E9E7-47DE-8DCE-7DD46B6B3CB1Q50115590-785DD897-CFD5-41D3-B86B-7400578E251CQ52927960-28A92444-B6C4-48BF-ABF1-731B29873F18Q54186062-6E93FA3E-7425-4F8E-9950-6E6F5EA651A9Q55060181-331A51CD-CBD8-4794-8B0D-8AF4BA393D92
P2860
Pharmacologic blockade of JAK1/JAK2 reduces GvHD and preserves the graft-versus-leukemia effect.
description
2014 nî lūn-bûn
@nan
2014 թուականի Հոկտեմբերին հրատարակուած գիտական յօդուած
@hyw
2014 թվականի հոտեմբերին հրատարակված գիտական հոդված
@hy
2014年の論文
@ja
2014年論文
@yue
2014年論文
@zh-hant
2014年論文
@zh-hk
2014年論文
@zh-mo
2014年論文
@zh-tw
2014年论文
@wuu
name
Pharmacologic blockade of JAK1 ...... graft-versus-leukemia effect.
@ast
Pharmacologic blockade of JAK1 ...... graft-versus-leukemia effect.
@en
Pharmacologic blockade of JAK1 ...... graft-versus-leukemia effect.
@nl
type
label
Pharmacologic blockade of JAK1 ...... graft-versus-leukemia effect.
@ast
Pharmacologic blockade of JAK1 ...... graft-versus-leukemia effect.
@en
Pharmacologic blockade of JAK1 ...... graft-versus-leukemia effect.
@nl
prefLabel
Pharmacologic blockade of JAK1 ...... graft-versus-leukemia effect.
@ast
Pharmacologic blockade of JAK1 ...... graft-versus-leukemia effect.
@en
Pharmacologic blockade of JAK1 ...... graft-versus-leukemia effect.
@nl
P2093
P2860
P1433
P1476
Pharmacologic blockade of JAK1 ...... graft-versus-leukemia effect.
@en
P2093
John F DiPersio
Julie Ritchey
Lynne Collins
Matthew Holt
Matthew L Cooper
P2860
P304
P356
10.1371/JOURNAL.PONE.0109799
P407
P577
2014-10-07T00:00:00Z